ProCE Banner Activity

Current and Novel Approaches to the Management of Patients With CLL/SLL and MCL Using BTK Inhibitors

Clinical Thought

In this commentary, Beth Faiman PhD, MSN, APRN-BC, AOCN, BMTCN, FAAN, FAPO, discusses key data for the expert management of CLL/SLL and MCL with BTK inhibitors and other targeted therapies.

Released: May 25, 2023

Share

Faculty

Beth Faiman

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center
Cleveland, Ohio

Provided by

Provided by Partners for Advancing Clinical Education (PACE) and Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Disclosure

Primary Author

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO

Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program, Case Comprehensive Cancer Center
Cleveland, Ohio

Beth Faiman, PhD, MSN, APRN-BC, AOCN, BMTCN, FAAN, FAPO: consultant/advisor/speaker: Bristol Myers Squibb, Janssen, Karyopharm, Pfizer.